ES2897500T8 - Formulaciones de anticuerpos T1h - Google Patents
Formulaciones de anticuerpos T1hInfo
- Publication number
- ES2897500T8 ES2897500T8 ES20174783T ES20174783T ES2897500T8 ES 2897500 T8 ES2897500 T8 ES 2897500T8 ES 20174783 T ES20174783 T ES 20174783T ES 20174783 T ES20174783 T ES 20174783T ES 2897500 T8 ES2897500 T8 ES 2897500T8
- Authority
- ES
- Spain
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2859CH2009 | 2009-11-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2897500T3 ES2897500T3 (es) | 2022-03-01 |
| ES2897500T8 true ES2897500T8 (es) | 2022-03-10 |
Family
ID=44059267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20174783T Active ES2897500T3 (es) | 2009-11-20 | 2010-11-19 | Formulaciones de anticuerpos T1h |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20120231009A1 (es) |
| EP (2) | EP3721904B1 (es) |
| JP (2) | JP5896471B2 (es) |
| KR (1) | KR101333276B1 (es) |
| CN (1) | CN102770157B (es) |
| AU (1) | AU2010320515B2 (es) |
| BR (1) | BR112012012080B1 (es) |
| CA (1) | CA2781467C (es) |
| CU (1) | CU20120080A7 (es) |
| DK (1) | DK3721904T3 (es) |
| ES (1) | ES2897500T3 (es) |
| IL (1) | IL219884A (es) |
| MX (1) | MX2012005863A (es) |
| MY (1) | MY165614A (es) |
| NZ (1) | NZ600096A (es) |
| PL (1) | PL3721904T3 (es) |
| PT (1) | PT3721904T (es) |
| RU (1) | RU2548772C2 (es) |
| WO (1) | WO2011061712A1 (es) |
| ZA (1) | ZA201204459B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2265644A4 (en) | 2008-03-14 | 2011-04-27 | Biocon Ltd | MONOCLONAL ANTIBODY AND CORRESPONDING METHOD |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| CA2825838C (en) | 2011-01-28 | 2020-10-27 | Sanofi | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| KR102238677B1 (ko) | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| PT2916866T (pt) | 2012-11-06 | 2018-07-10 | Amgen Inc | Formulação para ativadores de células t bispecíficas (bites) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| DK3024485T3 (da) | 2013-07-23 | 2020-12-07 | Biocon Ltd | Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå |
| CN110496099B (zh) | 2013-09-11 | 2022-06-21 | 伊戈尔生物药品股份有限公司 | 包含粘度降低剂的液体蛋白质制剂 |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
| EP3169353B1 (en) | 2014-07-16 | 2019-12-18 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| MX2017004306A (es) | 2014-10-01 | 2017-12-20 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| CN104922668B (zh) * | 2014-12-10 | 2019-08-23 | 信达生物制药(苏州)有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| AU2017333367A1 (en) * | 2016-09-27 | 2019-04-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| CN106800598B (zh) * | 2017-02-09 | 2020-08-07 | 广州桂雨生物科技有限公司 | 一种抗体保存液及其制备方法 |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| US11498626B2 (en) * | 2020-11-11 | 2022-11-15 | Rivian Ip Holdings, Llc | Vehicle tailgate assembly |
| CN113289027B (zh) * | 2021-05-18 | 2022-07-01 | 中国兽医药品监察所 | 一种通用型单克隆抗体耐热保护剂 |
| WO2024083074A1 (en) * | 2022-10-17 | 2024-04-25 | Beigene, Ltd. | Formulations containing anti-tigit antibody and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| PT1516628E (pt) * | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US5810597A (en) * | 1996-06-21 | 1998-09-22 | Robert H. Allen, Jr. | Touch activated audio sign |
| ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| EP1610820B2 (en) * | 2003-04-04 | 2013-08-21 | Genentech, Inc. | High concentration antibody and protein formulations |
| CA2626082C (en) * | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| CA2654794A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| BRPI0721097A2 (pt) * | 2006-12-11 | 2014-07-01 | Hoffmann La Roche | Formulação parenteral de anticorpo abeta |
| CN101199483B (zh) * | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| EP2119453B1 (en) * | 2006-12-26 | 2015-05-20 | Centro de Inmunolgía Molecular | Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia |
| CN101600457B (zh) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
-
2010
- 2010-11-19 RU RU2012125254/15A patent/RU2548772C2/ru active
- 2010-11-19 BR BR112012012080-8A patent/BR112012012080B1/pt active IP Right Grant
- 2010-11-19 WO PCT/IB2010/055296 patent/WO2011061712A1/en active Application Filing
- 2010-11-19 MX MX2012005863A patent/MX2012005863A/es active IP Right Grant
- 2010-11-19 MY MYPI2012002248A patent/MY165614A/en unknown
- 2010-11-19 EP EP20174783.9A patent/EP3721904B1/en active Active
- 2010-11-19 US US13/510,929 patent/US20120231009A1/en not_active Abandoned
- 2010-11-19 NZ NZ600096A patent/NZ600096A/xx unknown
- 2010-11-19 PT PT201747839T patent/PT3721904T/pt unknown
- 2010-11-19 CA CA2781467A patent/CA2781467C/en active Active
- 2010-11-19 AU AU2010320515A patent/AU2010320515B2/en active Active
- 2010-11-19 PL PL20174783T patent/PL3721904T3/pl unknown
- 2010-11-19 ES ES20174783T patent/ES2897500T3/es active Active
- 2010-11-19 CN CN201080060508.0A patent/CN102770157B/zh active Active
- 2010-11-19 EP EP10831248.9A patent/EP2501408B1/en active Active
- 2010-11-19 DK DK20174783.9T patent/DK3721904T3/da active
- 2010-11-19 JP JP2012539465A patent/JP5896471B2/ja active Active
- 2010-11-19 KR KR1020127015910A patent/KR101333276B1/ko active IP Right Grant
-
2012
- 2012-05-20 IL IL219884A patent/IL219884A/en active IP Right Grant
- 2012-05-21 CU CU2012000080A patent/CU20120080A7/es unknown
- 2012-06-18 ZA ZA2012/04459A patent/ZA201204459B/en unknown
-
2015
- 2015-12-28 JP JP2015256586A patent/JP2016104780A/ja active Pending
-
2018
- 2018-11-20 US US16/197,228 patent/US20190321285A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,316 patent/US20210290525A1/en not_active Abandoned
-
2023
- 2023-05-19 US US18/199,675 patent/US20240058263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2897500T8 (es) | Formulaciones de anticuerpos T1h | |
| BRPI1006519A2 (pt) | formulação de anticorpos | |
| BRPI0814003A2 (pt) | Formulações de anticorpo | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| BRPI0922730A2 (pt) | formulação de anticorpo | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| DK2459167T3 (da) | SUBKUTAN ANTI-HER2-antistofformulering | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| FIC20230025I1 (fi) | neratinibi | |
| DK2482768T3 (da) | Intrauterint system | |
| BRPI1014388A2 (pt) | preparação de sólido. | |
| EP2588141A4 (en) | ANTIBODY FORMULATIONS | |
| BRPI1009465A2 (pt) | Formulação | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| BRPI0912769A2 (pt) | anticorpos anti-pirb | |
| BRPI1010159A2 (pt) | bistuti | |
| BRPI0908455A2 (pt) | formulações de flibanserina | |
| FI9631U1 (fi) | Yleisömittausjärjestelmä | |
| ES1070429Y (es) | Traspaleta mejorada | |
| BRPI1013462A2 (pt) | Formulações herbicidas | |
| BR112012003616A2 (pt) | metilpirroloprimidinacarboxamidas |